On the basis of these findings, we proposed that the therapy should be adjusted accordingly: gliomas with p53wt status should preferably be treated with TMZ, while those with p53mt (without transactivation activity of the protein) should be treated with CCNU or a combination of TMZ/CCNU [118] (Figure 4). This evidence concerns the gene CCNO and central nervous system cancer.